Puskarmula (Inula racemosa)

Puskarmula (Inula racemosa) is an Ayurvedic root herb whose primary bioactive sesquiterpene lactones, including alantolactone and isoalantolactone, drive its therapeutic effects. These compounds inhibit mast cell degranulation, modulate inflammatory pathways, and demonstrate insulin-sensitizing activity in preclinical models.

Origin & History

Puskarmula (Inula racemosa) is a perennial herb native to the Himalayan regions of India, Pakistan, and Afghanistan. It primarily uses the root or rhizome, which is harvested from wild-crafted plants and processed into powder or essential oil through hydrodistillation.

Historical & Cultural Context

In Ayurveda, Puskarmula has been used historically for respiratory issues and Kapha imbalances, including as an expectorant and bronchodilator. It is also applied in Unani and Tibetan systems for cardiovascular and digestive support.

Health Benefits

• May lower plasma insulin and glucose levels, as shown in animal models [2]. • Demonstrates antibacterial activity in vitro [2]. • Exhibits hepatoprotective effects by reducing elevated liver enzymes in animal studies [2][5]. • Acts as an anti-inflammatory and antihistaminic agent through mast cell degranulation inhibition [1][2][5]. • Traditionally used as a bronchodilator and expectorant in Ayurvedic medicine [1].

How It Works

Alantolactone and isoalantolactone, the principal sesquiterpene lactones in Inula racemosa root, suppress NF-κB signaling and inhibit COX-mediated prostaglandin synthesis, producing anti-inflammatory effects. The herb reduces mast cell degranulation, thereby blocking histamine release and dampening Type I hypersensitivity responses. Its hypoglycemic activity appears linked to enhanced peripheral glucose uptake and modulation of insulin receptor sensitivity, as demonstrated in streptozotocin-induced diabetic animal models.

Scientific Research

There are no specific human clinical trials, RCTs, or meta-analyses available in the current research for Puskarmula. The evidence is limited to traditional uses and preclinical animal/in vitro studies.

Clinical Summary

Most available evidence for Puskarmula comes from in vitro assays and rodent models rather than human clinical trials, limiting the strength of conclusions. Animal studies have shown statistically significant reductions in plasma glucose and insulin levels following root extract administration, alongside normalization of elevated hepatic enzymes (ALT, AST) indicating hepatoprotective action. Antibacterial activity has been confirmed in vitro against several gram-positive and gram-negative strains, though minimum inhibitory concentrations and clinical relevance remain incompletely characterized. No large-scale, randomized controlled human trials have been published to date, and current evidence should be regarded as preliminary.

Nutritional Profile

Puskarmula (Inula racemosa) is a medicinal root herb rather than a dietary food source, so conventional macronutrient profiling is limited; however, the following bioactive and phytochemical composition is documented: Primary bioactive compounds include sesquiterpene lactones — most notably Alantolactone and Isoalantolactone (collectively 1–3% of dried root extract by weight), which are the principal pharmacologically active constituents responsible for anti-inflammatory, bronchodilatory, and hepatoprotective effects. Inulin (a fructooligosaccharide/prebiotic fiber) is present at approximately 35–44% of dry root weight, contributing to its fiber content and gut microbiome modulation potential; bioavailability of inulin is low in the small intestine but high in the colon via fermentation. Essential oils constitute roughly 1–4% of dry weight, containing camphor, azulene, and beta-sitosterol as key components. Beta-sitosterol (~0.1–0.3% dry weight) contributes to anti-inflammatory and lipid-modulating activity. Isocostunolide and dihydroisoalantolactone are additional sesquiterpene lactones identified in trace quantities (<0.5%). Phenolic acids including chlorogenic acid and caffeic acid are present in modest amounts (~50–200 mg/100g dry weight). Alkaloid content is minimal and not well-quantified. Mineral content of the root includes calcium (~300–500 mg/100g dry weight), potassium (~400–600 mg/100g dry weight), magnesium (~80–150 mg/100g dry weight), and iron (~10–20 mg/100g dry weight), based on general Inula species root analyses. Protein content is low, approximately 4–7% of dry weight, with limited essential amino acid profiling available. Fat content is minimal (<2% dry weight). Carbohydrates (primarily inulin and other polysaccharides) dominate the dry weight at 50–60%. Bioavailability note: Sesquiterpene lactones show moderate oral bioavailability enhanced by lipid co-administration; inulin passes largely undigested to the colon; phenolic compounds have variable absorption (10–40%) depending on gut microbiota composition. Standardized extracts are typically normalized to alantolactone and isoalantolactone content for therapeutic use.

Preparation & Dosage

No clinically studied dosage ranges are available from human trials. Traditional Ayurvedic use involves root powder, but specific quantities are not detailed. Essential oil extracts contain sesquiterpene lactones, used in some antiulcer drugs, though dosing is unspecified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Tulsi, Ashwagandha, Turmeric, Ginger, Licorice

Safety & Interactions

Puskarmula has not been rigorously evaluated for safety in human clinical trials, so a formal adverse-effect profile is incomplete. Due to its demonstrated hypoglycemic activity in animal models, concurrent use with antidiabetic medications (e.g., metformin, sulfonylureas, insulin) may risk additive blood glucose lowering. The herb is contraindicated during pregnancy based on traditional Ayurvedic cautions and the lack of safety data, and it should be avoided in individuals with known allergies to plants in the Asteraceae (daisy) family given potential cross-reactivity with sesquiterpene lactones. Individuals with liver conditions should consult a healthcare provider before use, despite its hepatoprotective preclinical profile.